$2.5 B

XLRN Mkt cap, 09-Nov-2018

$3.3 M

Acceleron Pharma Revenue Q3, 2018
Acceleron Pharma Net income (Q3, 2018)-29 M
Acceleron Pharma EBIT (Q3, 2018)-30.1 M
Acceleron Pharma Cash, 30-Sep-2018112.4 M

Acceleron Pharma Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

57.2m14.6m18.1m27.8m13.5m

Revenue growth, %

(74%)24%53%

R&D expense

36.1m58.4m68.6m89.7m

General and administrative expense

14.2m20.6m25.3m33.7m

Operating expense total

50.3m79.0m93.9m123.5m

EBIT

7.0m(55.5m)(60.9m)(66.1m)(110.0m)

EBIT margin, %

12%(379%)(336%)(238%)(816%)

Interest expense

2.1m922.0k

Interest income

39.0k83.0k512.0k1.9m2.6m

Pre tax profit

(21.9m)(51.3m)(63.9m)(57.0m)(108.4m)

Income tax expense

(24.0k)(32.0k)

Net Income

(21.9m)(51.3m)(63.9m)(57.0m)(108.5m)

Acceleron Pharma Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

113.2m176.5m27.8m21.0m100.2m

Accounts Receivable

11.5m

Inventories

2.2m2.5m2.5m3.9m

Current Assets

119.0m182.3m110.9m146.8m285.2m

PP&E

3.7m3.1m3.1m5.2m7.0m

Total Assets

123.7m186.3m146.3m247.6m389.2m

Accounts Payable

885.0k724.0k875.0k1.6m1.1m

Current Liabilities

27.2m9.3m14.5m16.1m16.7m

Long-term debt

16.9m

Total Debt

16.9m

Total Liabilities

65.9m37.1m22.1m24.0m

Additional Paid-in Capital

250.1m399.8m416.9m590.5m839.1m

Retained Earnings

(192.3m)(243.6m)(307.5m)(364.5m)(473.0m)

Total Equity

57.8m156.3m109.3m225.6m365.2m

Financial Leverage

2.1 x1.2 x1.3 x1.1 x1.1 x

Acceleron Pharma Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(21.9m)(51.3m)(63.9m)(57.0m)(108.5m)

Depreciation and Amortization

915.0k1.1m1.2m1.7m2.8m

Inventories

(823.0k)(255.0k)7.0k(1.4m)

Accounts Payable

(53.0k)(161.0k)151.0k644.0k(504.0k)

Cash From Operating Activities

(19.6m)(53.2m)(44.2m)(44.7m)(76.7m)

Purchases of PP&E

(307.0k)(514.0k)(959.0k)(3.4m)(4.4m)

Cash From Investing Activities

(307.0k)(514.0k)(109.0m)(108.8m)(64.4m)

Long-term Borrowings

(3.7m)(16.3m)

Cash From Financing Activities

93.5m117.0m4.5m146.7m220.3m

Interest Paid

1.7m1.6m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(9.1m)(10.4m)(11.9m)5.1m(17.0m)(37.7m)(25.4m)(55.1m)(80.5m)(26.2m)(55.2m)(84.1m)

Depreciation and Amortization

265.0k324.0k715.0k1.2m541.0k1.2m2.0m904.0k1.9m2.9m

Accounts Payable

891.0k1.4m2.6m3.3m1.6m1.8m2.6m(42.0k)(309.0k)1.2m(778.0k)71.0k(566.0k)591.0k183.0k80.0k

Cash From Operating Activities

(12.5m)(14.9m)(28.0m)(39.1m)(55.9m)(23.4m)(45.6m)(65.7m)

Purchases of PP&E

(150.0k)(489.0k)(1.6m)(2.2m)(677.0k)(2.9m)(3.6m)(504.0k)(1.4m)(1.9m)

Cash From Investing Activities

(150.0k)(106.9m)(118.2m)(113.7m)32.6m47.1m82.1m(11.9m)18.1m63.2m

Long-term Borrowings

(16.3m)

Cash From Financing Activities

113.6m141.9m142.3m144.9m1.5m1.8m191.8m4.9m7.0m15.3m

Interest Paid

1.6m

Acceleron Pharma Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Acceleron Pharma Operating Metrics

FY, 2015FY, 2016

Phase III Trials Products

2 2
Report incorrect company information

Acceleron Pharma Employee Rating

4.420 votes
Culture & Values
4.7
Work/Life Balance
4.5
Senior Management
4.3
Salary & Benefits
4.3
Career Opportunities
4.2
Source